Abstract
A high throughput chemical screening campaign has led to the identification of 3-aminobenzo[b]thiophene-2-carboxamides as LIMK1 inhibitors. Evolution of bicyclic hits to the tricyclic 4-aminobenzothieno[3,2-d]pyrimidine, using a traditional medicinal chemistry SAR guided approach, resulted in a significant increase in potency. Further elaboration has seen the 7-phenyl-4- aminobenzothieno[3,2-d]pyrimidine emerge as a LIMK1 inhibitor lead candidate.
| Original language | English |
|---|---|
| Pages (from-to) | 977 - 981 |
| Number of pages | 5 |
| Journal | MedChemComm |
| Volume | 2 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2011 |
| Externally published | Yes |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver